Monoclonal antibody 2G9 for resisting H10 subtype influenza virus hemagglutinin protein and application thereof
By using hybridoma cell technology and quantum dot fluorescent microsphere detection technology, a monoclonal antibody against H10 subtype influenza virus was developed, which solved the problems of long detection time and high equipment requirements of existing detection methods, and realized rapid and sensitive virus detection.
Patent Information
- Application Number
- CN202411066643.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-05
AI Technical Summary
Existing influenza virus detection methods are technically demanding and time-consuming, making it difficult to quickly and accurately detect H10 subtype influenza viruses, thus affecting the control of influenza epidemics.
A hybridoma cell line that stably secretes monoclonal antibody hemagglutinin protein against H10 subtype influenza virus was established using hybridoma cell technology. Combined with quantum dot fluorescent microsphere detection technology, a rapid and sensitive detection method was developed.
It enables rapid, sensitive, and accurate detection of the H10 subtype influenza virus, simplifies the operation process, reduces equipment and technical requirements, and improves detection efficiency.
Smart Images

Figure CN118978587A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and relates to anti-H10 subtype influenza virus hemagglutinin protein monoclonal antibody 2G9 and application thereof. The present invention utilizes cell engineering and antibody engineering technologies to obtain a hybridoma cell line that secretes a monoclonal antibody against the hemagglutinin protein, induces ascites in mice of the same strain, prepares the monoclonal antibody 2G9 against the hemagglutinin protein, identifies it as IgG2a, κ type, and then realizes application of the antibody through affinity purification, immunization method and other technologies. Background Art
[0002] Influenza is the most widespread zoonosis in the world, causing great harm to the health of both humans and animals. Influenza A virus is one of the main pathogens causing influenza and belongs to the family of Orthomyxoviridae. According to the antigenic characteristics of hemagglutinin (HA) and neuraminidase (NA) proteins, influenza A virus is divided into 18 HA and 11 NA subtypes. The host range of influenza A virus is very wide. It has been detected and isolated in many species such as humans, poultry, pigs, and horses. Waterfowl are considered to be the natural host of influenza A virus, and most influenza A virus subtypes have been found in waterfowl. In recent years, H10 subtype influenza virus has been widely prevalent in poultry, and multiple recombination has occurred. More and more H10 subtype influenza viruses have been isolated from poultry. Since 2004, human cases of infection with H10N7 subtype influenza virus have appeared in Egypt and Australia. In 2013, two deaths of human infection with H10N8 subtype influenza virus were first reported in China. Subsequently, H10 subtype influenza virus infection was also found in European seals. In June 2021, the National Health Commission of China reported that a case of human infection with H10N3 subtype influenza was found in Jiangsu Province; in June 2022, the Zhejiang Provincial Health Commission also reported a case of human infection with H10N3 subtype influenza in Jinhua, Zhejiang; in January 2024, Zhejiang Province isolated H10N5 subtype influenza virus from samples of influenza deaths. Therefore, H10 subtype influenza virus poses a potential pandemic threat to global public health. At present, H10 subtype influenza virus continues to spread among poultry around the world. Therefore, it is of great significance for influenza prevention and control to establish a rapid, accurate and sensitive method for detecting H10 subtype influenza virus and effectively detect and identify various poultry samples.
[0003] Isolating influenza virus by chicken embryo or MDCK cells is the most classic method for identifying influenza virus. In recent years, molecular detection methods have been greatly developed, and real-time quantitative polymerase chain reaction has been widely used in laboratory diagnosis of influenza virus infection, but these methods are very demanding on personnel operation techniques and equipment and are very time-consuming. With the continuous development of monoclonal antibody technology, detection methods based on monoclonal antibodies are also widely used in virus detection. Therefore, the present invention aims to illustrate a specific monoclonal antibody for H10 subtype influenza virus hemagglutinin protein, and combines it with quantum dot fluorescent microsphere detection technology, and can detect H10 subtype influenza virus in sample. The above method has the advantages of fast, sensitive, accurate and economical, which will be conducive to earlier and faster discovery of H10 subtype influenza virus, and contribute to the effective control of influenza epidemic.
[0004] In summary, the development of anti-H10 subtype influenza virus monoclonal antibodies and the establishment of rapid and sensitive detection methods are of great significance for the prevention and control of the virus. Based on the above background, this project selected the H10 subtype influenza virus hemagglutinin protein as the target antigen, used fusion hybridoma technology to establish a hybridoma cell line that stably secretes anti-hemagglutinin protein monoclonal antibodies, and prepared, purified and identified these monoclonal antibodies in large quantities. The successful acquisition of this monoclonal antibody has laid a material foundation for the establishment of a new H10 subtype influenza virus diagnostic method-quantum dot fluorescent microsphere immunochromatographic strip diagnosis. At the same time, it plays an important role in the study of disease pathogenesis, prognosis and efficacy determination.
[0005] The present invention uses hybridoma cell technology. This technology fuses B lymphocytes of immune mice with myeloma cells SP2 / 0 to establish a hybridoma cell line that secretes homogeneous antibodies, also known as monoclonal antibody technology. This technology involves a series of methods such as animal immunization, cell culture, cell fusion, cell cloning culture and immunoassay. Summary of the invention
[0006] The purpose of the present invention is to provide an anti-H10 subtype influenza virus hemagglutinin protein monoclonal antibody capable of identifying H10 subtype influenza virus.
[0007] The anti-H10 subtype influenza virus hemagglutinin protein monoclonal antibody 2G9 has a monoclonal antibody subtype of IgG2a, κ type, named 2G9, and can specifically recognize the hemagglutinin protein of the H10 subtype influenza virus. The amino acid sequence of the antibody's heavy chain variable region is shown in SEQ ID No.2, and the amino acid sequence of the light chain variable region is shown in SEQ ID No.4.
[0008] The monoclonal antibody is produced by hybridoma cells. The hybridoma cells producing the monoclonal antibody are hybridoma cell lines 2G9 obtained by fusion, screening, cloning and stable passage of immune BALB / C mouse spleen lymphocytes and mouse myeloma cells SP2 / 0, and can stably secrete monoclonal antibody 2G9 against H10 subtype influenza virus hemagglutinin protein.
[0009] SEQ ID No.1
[0010] Heavy chain:DNA sequence(375bp)
[0011] Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
[0012] CAGGTTACTCTGAAAGAGTCTGGCCCTGGGATATTGCAGCCCTCCCAGACCCTCAGTCTGACTTGT
[0013] TCTTTCTCTGGGTTTTCACTGAGCACTTCTGGTATGGGTGTGAGCTGGATTCGTCAGCCTTCAGGA
[0014] AAGGGTCTGGAATGGCTGACACACATTTACTGGGATGATGACAAGCGCTATAACCCATCCCTGAA
[0015] GAGCCGGCTCACAATCTCCAAGGATACCTCCAGAAACCAGGTATTCCTCAAGATCACTAGTGTGG
[0016] ACACTGCAGATACTGCCACATACTACTGTGCTCGAAGCCCCCTACGGACTACGGTAGTAGCTGG
[0017] GGTGTTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA
[0018] SEQ ID No.2
[0019] Heavy chain:Amino acid sequence(125AA)
[0020] Signal peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
[0021] QVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWLTHIYWDDDKRYNPSLKSRLTISKDT
[0022] SRNQVFLKITSVDTADTATYYCARSPPTDYGSSWGVMDYWGQGTSVTVSS
[0023] SEQ ID No.3
[0024] Light chain:DNA sequence(366bp)
[0025] Signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
[0026] CAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGACAGACAGTCAAGATCTCCTGCAAGGCTTCTGGGTTTACCTTCACAAACTATGGAATGAACTGGGTGAGGCAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATACACACTTACAATGGAGAGCCAGCATATGCTGAAGACTTCAAGGGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAGATCAACAACCTCAAGAATGAGGACACGGCTACATATTTCTGTGCAAGAGGCTATGATTACGCCGAGGGTTACTTTGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA
[0027] SEQ ID No.4
[0028] Light chain:Amino acid sequence(122AA)
[0029] Signal peptide-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
[0030] QIQLVQSGPELKKPGQTVKISCKASGFTFTNYGMNWVRQAPGKGLKWMGWIHTYNGEPAYAEDFKGRFAFS
[0031] LETSASTAYLQINNLKNEDTATYFCARGYDYAEGYFAMDYWGQGTSVTVSS
[0032] The second object of the present invention is to provide a method for preparing anti-H10 subtype influenza virus hemagglutinin protein monoclonal antibodies, which is achieved by the following steps and technical solutions:
[0033] (1) Animal immunization: 8-week-old BALB / C mice were selected and immunized with purified hemagglutinin protein of H10N7 subtype influenza virus (A / chicken / Zhejiang / 2CP8 / 2014).
[0034] (2) Cultivation of mouse myeloma cells: Mouse myeloma cells SP2 / 0 were cultured and maintained in a good growth state for cell fusion.
[0035] (3) Cell fusion: Cell fusion mediated by polyethylene glycol is used. The mice selected in step (1) are killed and spleen lymphocytes are obtained. The SP2 / 0 cells in step (2) are collected, the two cells are mixed and centrifuged, and then the cells are fused by polyethylene glycol. The fused cells are appropriately diluted, inoculated into a 96-well culture plate, and cultured under appropriate conditions.
[0036] (4) Screening of hybridoma cells: The above culture was cultured in a hypoxanthine-phosphoribosyltransferase selective medium. When the cell colonies grew to a suitable size, the cell culture supernatant was aspirated for antibody identification and positive clones were screened.
[0037] (5) Cloning of hybridoma cells: clone positive hybridoma cells by limiting dilution method, inoculate the cells diluted to a certain density into 96-well cell culture plates, and make only one cell grow in each well. Take the supernatant from the wells where cell colonies are formed for enzyme-linked immunosorbent assay to screen and identify positive clones. Select the culture wells with the highest antibody titer and single clone cell growth, perform limiting dilution again, perform limiting dilution more than 3 times in a row, and continuously passage for more than 20 generations to obtain hybridoma cell lines that stably and efficiently express monoclonal antibodies against H10 subtype influenza virus. Perform antibody identification and physical and chemical property analysis on the cloned hybridoma cells.
[0038] (6) Preparation of monoclonal antibody ascites: 10-week-old healthy BALB / C mice were selected and 5 million positive hybridoma cells were inoculated in each abdomen. About 10 days after the inoculation of the cells, the abdomen of the mice was significantly swollen. The health status and abdominal signs of the mice were closely observed. When the ascites was as much as possible and the mice were on the verge of death, the ascites was collected and centrifuged to determine the antibody titer and purify the monoclonal antibodies in the ascites.
[0039] (7) Purification of monoclonal antibodies: Monoclonal antibodies were purified from mouse ascites using protein G agarose gel affinity purification.
[0040] (8) The present invention obtains a hybridoma line, namely 2G9, which produces monoclonal antibodies to the hemagglutinin protein of the H10 subtype influenza virus. The 2G9 hybridoma cell line was cloned three times and cultured for 6 months. The secretion of antibodies was stable. The cell line was frozen in liquid nitrogen and grew well after recovery. The titer of the 2G9 culture supernatant was 1:128 and the titer of the ascites was 1:2048 measured by enzyme-linked immunosorbent assay. The monoclonal antibody immunoglobulin subtype analysis showed that the antibody type produced by the hybridoma cell was IgG2a.
[0041] The invention provides a hybridoma cell producing a monoclonal antibody, which is a mouse hybridoma cell line 2G9 obtained by fusing immune BALB / C mouse spleen cells and mouse myeloma cells SP2 / 0, screening, cloning and passage, and can stably secrete the monoclonal antibody 2G9 against the hemagglutinin protein of H10 subtype influenza virus.
[0042] Another object of the present invention is to provide the use of monoclonal antibody 2G9 in the preparation of H10 subtype influenza virus detection products.
[0043] The detection of the monoclonal antibody 2G9 in poultry throat swabs, feces, allantoic fluid or other environmental samples containing H10 subtype influenza virus is achieved through quantum dot fluorescent microsphere immunochromatography technology.
[0044] The present invention provides a monoclonal antibody 2G9 against H10 subtype influenza virus hemagglutinin protein and its application in quantum dot fluorescent microsphere immunochromatographic strip detection. Purified H10 subtype influenza virus hemagglutinin protein is used to immunize BALB / C mice, immune BALB / C mouse B lymphocytes are collected and fused with mouse myeloma cells, positive clones are determined by enzyme-linked immunosorbent assay, and hybridoma cell line 2G9 secreting monoclonal antibodies against H10 subtype influenza virus hemagglutinin protein is established, positive cells are amplified and cultured and injected into the peritoneal cavity of mice of the same strain to induce the production of antibody-containing ascites, and ascites is collected and affinity purified with antibodies to obtain monoclonal antibody 2G9 against H10 subtype influenza virus hemagglutinin protein. The heavy chain amino acid sequence of the antibody is shown in SEQ ID No.1, and the light chain amino acid sequence is shown in SEQ ID No.2. The monoclonal antibody is further analyzed and identified for physical and chemical properties, and a method for detecting H10 subtype influenza virus by quantum dot fluorescent microsphere immunochromatographic strip technology using the monoclonal antibody as a probe is established. The present invention provides an effective tool for auxiliary diagnosis of H10 subtype influenza virus infection in clinical samples, and can be widely applied to various detection technologies as well as clinical and experimental research.
[0045] The invention has the advantages of providing a monoclonal antibody to the hemagglutinin protein of 2G9 subtype influenza virus, a simple and easy preparation method, and more importantly, the monoclonal antibody prepared by the method can have multiple uses, such as qualitative diagnosis of H10 subtype influenza samples in clinics and laboratories.
[0046] Instruction Manual
[0047] Figure 1 Immunoglobulin subtype analysis of monoclonal antibody 2G9.
[0048] Figure 2 The specificity of quantum dot immunochromatographic strip in detecting H10 subtype influenza virus.
[0049] Figure 3 The sensitivity of quantum dot immunochromatographic strip in detecting H10 subtype influenza virus. DETAILED DESCRIPTION
[0050] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0051] Example 1. Preparation of monoclonal antibodies against H10 subtype influenza virus hemagglutinin protein
[0052] (1) Immunization of mice: For the first immunization, the H10 subtype influenza virus hemagglutinin protein and adjuvant were mixed evenly in a volume ratio of 1:1, with a total volume of 0.5 ml. 0.1 ml (containing 5 μg of H10 subtype influenza virus hemagglutinin protein antigen) was injected into the inner thigh muscle of each BALB / C mouse. On the 21st day, a booster immunization was performed in the same manner. On the 35th day, a small amount of tail blood was collected for ELISA. The highest antibody titer reached 1:32000. The mouse with the highest antibody titer was selected for a booster immunization by tail vein injection, and cell fusion was performed 3 days later.
[0053] (2) Culture and subculture of mouse myeloma cells SP2 / 0: SP2 / 0 myeloma cells from BALB / C mice were cultured and subcultured in DMEM medium containing 10% bovine serum in a 37°C incubator containing 5% carbon dioxide. Subculture was usually not performed one day before fusion to ensure that the cells entered the logarithmic growth phase at the time of fusion.
[0054] (3) Cell fusion: BALB / C mouse peritoneal macrophages were used as feeder cells. One day before fusion, BALB / C mouse peritoneal macrophages were inoculated into 96-well culture plates and cultured for one day in hypoxanthine-guanine-phosphoribosyltransferase medium containing 20% bovine serum. The spleen of the mouse was taken 3 days after the last booster immunization, and the spleen lymphocytes were separated by pressure injection. The cells were washed by centrifugation and resuspended in DMEM culture medium. SP2 / 0 cells were collected, centrifuged, washed, resuspended in DMEM culture medium, and counted. 300 million spleen lymphocytes of immune mice were mixed with 30 million mouse myeloma cells SP2 / 0. The two cells were mixed, centrifuged and the supernatant was discarded. The centrifuge tube was rubbed to loosen the cell clumps. Polyethylene glycol preheated at 37°C was slowly added into the fusion tube. The centrifuge tube was gently shaken during this period. The cells were sucked into the fusion tube. After standing for 90 seconds, the cells were blown into the centrifuge tube. Then, according to the principle of slow first and fast later, 1 ml of DMEM medium was added within the first minute, 2 ml of DMEM medium was added within the second minute, and 7 ml of DMEM medium was added within the third minute. Then, 40 ml of DMEM medium preheated at 37°C was gradually added within 1 minute. Centrifuge at 800 rpm for 10 minutes. Then, hypoxanthine-guanine-phosphoribosyltransferase medium containing 20% bovine serum was added, and the cells were inoculated into 96-well culture plates with feeder cells using a glass dropper. Generally, two plates were spread for each fusion of cells and cultured in a 37°C incubator containing 5% carbon dioxide.
[0055] (4) Screening of hybridoma cells: After 5 days, the 96-well culture plate was replaced with half of the medium (containing hypoxanthine-guanine-phosphoribosyltransferase) and after 10 days, the culture medium containing hypoxanthine-phosphoribosyltransferase was used. The fused hybridoma cells were cultured in the selective culture medium containing hypoxanthine-phosphoribosyltransferase for about two weeks. When the cell colonies grew to an appropriate size (observed under a 10x objective, the size of the cell clones should be sufficient to fill a field of view), the cell culture supernatant was aspirated for ELISA to screen positive clones. The ELISA method was used to indirectly screen positive hybridoma clones. Main steps: ① dilute H10 subtype hemagglutinin protein with 0.01 mol / L pH 9.6 carbonate buffer, then add 0.1 ml per well to a 96-well ELISA plate, with a protein amount of 20 ng per well, overnight at 4°C; ② wash the plate 5 times with 0.01 mol / L pH 7.4 phosphate buffer (containing Tween 20); ③ use 0.01 mol / L pH 7.4 phosphate buffer containing 5% bovine serum albumin to 7.4 phosphate buffer was blocked for 2 hours; ④ the plate was washed 3 times; ⑤ the hybridoma culture supernatant was added, 0.1 ml per well, and a positive control (H10 subtype protein immune mouse serum), a negative control (SP2 / 0 culture supernatant) and a blank control were set up, and the reaction was carried out at room temperature for 2 hours; ⑥ the plate was washed 3 times; ⑦ 1:10000 diluted horseradish peroxidase-labeled goat anti-mouse IgG was added, 0.1 ml per well, and the reaction was carried out at room temperature for 1 hour; ⑧ the plate was washed 3 times; ⑨ the color developing solution was added and the reaction was carried out at room temperature in the dark for 5 minutes; ⑩ 2 mol / L sulfuric acid was used to terminate the reaction; the optical density value was measured at 450 nm, and the measured value divided by the negative value ≥ 2.1 was considered positive.
[0056] (5) Cloning of hybridoma cells: The cloning culture of hybridoma cells is carried out according to the limiting dilution method. After appropriate proliferation, the cells are accurately counted. The cell suspension diluted with complete DMEM medium to 10 / ml is inoculated into a 96-well culture plate with feeder cells, 0.1 ml per well. After 10 days, the cell growth is observed and the antibody level in the supernatant is detected. The culture well with the highest antibody titer and single clone cell growth is selected and limited dilution is performed again. The limiting dilution is performed for more than 3 times continuously and the cells are continuously passaged for more than 20 generations to obtain a hybridoma cell line that stably and efficiently expresses monoclonal antibodies against H10 subtype influenza virus.
[0057] (6) Preparation of monoclonal antibody ascites: 10-week-old healthy BALB / C mice were selected and phosphate-buffered saline containing 5 million positive hybridoma cells was inoculated in each abdomen. Ten days after cell inoculation, the abdomen of the mice was significantly swollen. The health status and abdominal signs of the mice were closely observed. The ascites of the mice were collected when as much as possible.
[0058] (7) Purification of monoclonal antibodies: Affinity purification (protein G agarose gel) was used to purify monoclonal antibodies in ascites. ① Treatment of ascites: Centrifuge the ascites at 4°C and 10,000 rpm for 15 minutes, remove the precipitate, collect the supernatant, mix it with 3 volumes of binding buffer, and centrifuge it at 4°C and 10,000 rpm for 15 minutes to remove the precipitate. Centrifuge it at 4°C and 10,000 rpm for 15 minutes to remove the precipitate. ② Wash the affinity purification column pre-loaded with protein G agarose gel thoroughly with 5 column volumes of binding buffer. ③ Load the diluted ascites onto the column and control the flow rate to 10 drops per minute. ④ Repeat the loading of the ascites that has passed through the column once. ⑤ Wash the purification column thoroughly with 5 column volumes of binding buffer. ⑥ Elute the bound monoclonal antibody with elution buffer, control the flow rate to 10 drops per minute, collect the eluate in a collection tube pre-added with 0.1 ml of potassium phosphate buffer (pH7.9), and collect 0.5 ml of antibody-containing eluate in each tube. ⑦ Detect the absorbance of each tube of eluate at 280 nanometers, and collect the eluate with a protein content greater than 0.1 mg per milliliter. ⑧ Add the antibody eluate to the ultrafiltration centrifuge tube, centrifuge at 4°C and 10,000 rpm for 20 minutes until the final volume of the antibody eluate is about 1 ml. Add 10 ml of 0.1 mol / L pH7.4 phosphate buffer, centrifuge at 8°C and 10,000 rpm for 20 minutes, and concentrate the antibody to a final volume of about 1 ml by centrifugation for the last time, and draw the antibody concentrate into the collection tube. ⑨ Dilute the desalted antibody solution and measure the protein content at 280 nanometers. ⑩ Dispense the purified antibody into small tubes and place in a low-temperature refrigerator for standby use.
[0059] (8) Identification of monoclonal antibody subtypes: The mouse monoclonal antibody immunoglobulin typing kit from Bio-Rad was used for analysis. The purified monoclonal antibody was appropriately diluted and tested, and the operation was strictly carried out according to the instructions of the kit. The test results showed that the monoclonal antibody secreted by the 2G9 hybridoma cells was IgG2a, κ type.
[0060] See attached for the results Figure 1 .
[0061] Example 2. Rapid detection of H10 subtype influenza virus using the monoclonal antibody
[0062] The H10 subtype influenza virus hemagglutinin protein monoclonal antibody prepared by the present invention can be used to quickly detect H10 subtype influenza virus, and the identification method can be achieved by the following method:
[0063] H10 subtype influenza virus immunochromatographic strip based on quantum dot fluorescent microspheres:
[0064] (1) Solution preparation: ① Activation buffer: Take a 100 ml glass bottle, add 0.488 g of N-morpholinoethanesulfonic acid, and add 100 ml of ultrapure water, and adjust the pH to 6.0; ② Preparation of coupling agent: Weigh 10 mg of N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and dissolve them in 1 ml of activation buffer, and prepare them before use; ③ Glass fiber membrane activation solution: Take a 100 ml glass bottle, add 1.5 ml of Tween 20, 4 g of sucrose, and 5 g of bovine serum ④ Blocking solution: add 0.2 ml Tween-20 and 1 g bovine serum albumin to 10 ml activation buffer, mix well and store at 4°C; ⑤ Antibody diluent: add 0.1 ml Tween 20 and 0.5 g bovine serum albumin to 10 ml activation buffer, mix well and store at 4°C; ⑥ Quantum dot resuspension: add 0.1 ml Tween 20 and 0.5 g bovine serum albumin to 10 ml phosphate buffer and adjust the pH to 7.2.
[0065] (2) Preparation of quantum dot markers: ① Take 40 μL of water-soluble carboxyl quantum dots and add them to a centrifuge tube containing 1 mL of activation buffer, and mix them by ultrasound for 10 minutes; ② Centrifuge the centrifuge tube at 15,000 rpm for 30 minutes, discard the supernatant after centrifugation, add 400 μL of activation buffer, mix them by ultrasound for 10 minutes, and add 15 μL of N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride in a ratio of 1:1, mix them by pipetting, and activate them on a horizontal shaker at room temperature and away from light for 30 minutes; ③ After activation, centrifuge the centrifuge tube at 15,000 rpm for 20 minutes, discard the supernatant after centrifugation, and add 400 μL of Activate the buffer and mix by ultrasound for 10 minutes; ④ Add 0.2 mg of labeled antibody (monoclonal antibody 2G9 against H10 subtype influenza virus) to the above solution and incubate on a horizontal shaker at room temperature in the dark for 1 hour; ⑤ After the incubation, add 410 μl of blocking solution and incubate on a horizontal shaker at room temperature in the dark for 1 hour; ⑥ After the blocking, centrifuge the centrifuge tube at 15,000 rpm for 30 minutes at 4°C, discard the supernatant after the centrifugation, add 1 ml of phosphate buffer and mix, centrifuge at 15,000 rpm for 20 minutes to remove unreacted antibody molecules; ⑦ After the centrifugation, discard the supernatant, add 150 μl of quantum dot buffer, mix by ultrasound for 10 minutes, and set aside.
[0066] (3) Preparation of glass fiber membrane: Soak the carrier glass cellulose membrane in the glass fiber membrane activation solution for 30 minutes and dry it in an oven at 37° C. After drying, spray the quantum dots in step 7 of (2) onto the glass fiber membrane.
[0067] (4) Preparation of nitrocellulose membrane: Goat anti-mouse IgG antibody and another monoclonal antibody 1E8 against H10 subtype influenza virus were diluted to 1 mg / mL and 2 mg / mL, respectively, and drawn on the quality control line and detection line of the nitrocellulose membrane to prepare a coating membrane, which was then dried in an oven at 37°C overnight.
[0068] (5) Assembly of the test card: First, install the nitrocellulose membrane coated with the detection monoclonal antibody and the quality control secondary antibody on a dedicated support plate, and then install the sample pad, glass fiber membrane, and absorbent pad in sequence. Leave a section of the glass fiber membrane and the absorbent pad on the nitrocellulose membrane, and leave a section of the sample pad on the glass fiber membrane. Ensure that each part is connected to each other so that the sample can flow smoothly. Cut the strips to prepare the detection quantum dot immunochromatographic strips. Each chromatographic strip is integrated into a plastic shell, and the fluorescence intensity excited by 365nm ultraviolet light is detected using a fluorescent immunochromatographic scanner.
[0069] (6) Determine the specificity of quantum dot immunochromatographic strips for detecting H10 subtype influenza virus: Quantum dot immunochromatographic strips were used to detect different virus allantoic fluid samples, including H1, H2, H3, H4, H5, H6, H7, H9, H11 subtype influenza viruses and several avian respiratory viruses such as Newcastle disease virus, infectious bronchitis virus, infectious bursal disease virus and avian paramyxovirus. The test results show that quantum dot immunochromatographic strips have good specificity for H10 subtype influenza virus.
[0070] See attached for the results Figure 2 .
[0071] (7) Determine the sensitivity of the quantum dot immunochromatographic strip in detecting H10 subtype influenza virus: dilute the H10 subtype influenza virus to 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, 0.0312, and 0.0156 hemagglutination units, and drip 80 microliters of the sample to be tested onto the sample pad area of the immunochromatographic strip. After 15 minutes, observe whether purple bands appear on the quality control line and the test line under 365-nanometer ultraviolet light. Result judgment: The appearance of a purple band on the quality control line indicates that the immunochromatographic strip is valid, otherwise it is invalid. The appearance of a purple band on the test line indicates that the sample contains H10 subtype influenza virus, otherwise it does not contain H10 subtype influenza virus. At the same time, a fluorescent immunochromatographic scanner can also be used to detect the fluorescence intensity excited by 365nm ultraviolet light. The absorbance value of the quality control line is greater than 1000 for valid, otherwise it is invalid; the absorbance value of the test line is greater than 800 for a positive result, and less than 800 for a negative result. The test results showed that the sensitivity of the quantum dot immunochromatographic strip in detecting H10 subtype influenza virus was 0.125 hemagglutination units.
[0072] See attached for the results Figure 3 .
[0073] (8) Comparative experiment between quantum dot immunochromatographic strip and other detection methods: A comparative analysis was conducted using the nucleic acid detection method of influenza virus H10 subtype, and clinical samples such as poultry throat swabs and feces were tested and analyzed. The specificity of the quantum dot immunochromatographic strip reached 100%. The quantum dot immunochromatographic strip detection method has the advantages of being fast, specific, and convenient, especially for various poultry samples, and has good clinical application prospects.
[0074] It should be understood that the present invention is described in conjunction with the best embodiment. However, after reading the above content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. An anti-H10 subtype influenza virus hemagglutinin protein monoclonal antibody 2G9, the antibody subtype is IgG2a, κ type, can specifically bind to the H10 subtype influenza virus hemagglutinin protein antigen, the antibody heavy chain variable region amino acid sequence is shown in SEQ ID No. 2, and the light chain variable region amino acid sequence is shown in SEQ ID No.
4.
2. The monoclonal antibody 2G9 according to claim 1, characterized in that: The monoclonal antibodies are produced by hybridoma cells.
3. The monoclonal antibody 2G9 according to claim 2, characterized in that: The hybridoma cell producing the monoclonal antibody is a hybridoma cell line 2G9 obtained by fusing, screening, cloning and stably propagating spleen lymphocytes of immune BALB / C mice and mouse myeloma cells SP2 / 0, and can stably secrete the monoclonal antibody 2G9 against the hemagglutinin protein of H10 subtype influenza virus.
4. The method for preparing the monoclonal antibody 2G9 against the hemagglutinin protein of H10 subtype influenza virus according to claim 1, characterized in that: The monoclonal antibody was obtained by the following steps: (1) Mouse immunization: 8-week-old BALB / C mice were selected and immunized with purified hemagglutinin protein of H10 subtype influenza virus; each mouse was immunized with 5 μg of H10 subtype influenza virus hemagglutinin protein mixed with adjuvant in a 1:1 ratio and injected into the inner thigh muscle. After 21 days, the mice were immunized again in the same manner. On the 35th day, the tail blood of the mice was collected to measure the antibody titer of the mice. The mice with the highest immune titer were selected and boosted once by tail vein injection. Cell fusion was performed 3 days later. (2) Cultivation of mouse myeloma cells: Two weeks before the fusion, myeloma cells SP2 / 0 were revived, cultured and maintained in a good growth state for hybridoma cell fusion; (3) Cell fusion: using polyethylene glycol-mediated cell fusion method; killing the mice selected in step (1) to obtain spleen lymphocytes; mixing spleen lymphocytes with myeloma cells SP2 / 0 cells and centrifuging them, and then merging the cells through polyethylene glycol-mediated cell fusion; appropriately diluting the fused cells, inoculating them into a culture plate, and culturing them under appropriate conditions; (4) Screening of hybridoma cells: The above culture is cultured in a selective medium containing hypoxanthine-phosphoribosyltransferase; when the cell colonies grow to an appropriate size, the culture supernatant is aspirated for antibody identification by enzyme-linked immunosorbent assay to screen positive clones; (5) Cloning and culture of hybridoma cells: clone positive hybridoma cells by limiting dilution method, inoculate the cells diluted to a certain density into 96-well cell culture plates so that only one cell grows in each well; take the supernatant of the wells where cell colonies are formed for enzyme-linked immunosorbent assay to screen and identify positive clones; select the culture wells with the highest antibody titer and single clone cell growth, perform limiting dilution again, perform monoclonal limiting dilution for more than 3 times in succession, and continuously passage for more than 20 generations to obtain hybridoma cell lines that stably and efficiently express monoclonal antibodies against H10 subtype influenza virus hemagglutinin protein; (6) Preparation of monoclonal antibody ascites: 10-week-old healthy BALB / C mice were selected and 5 million positive hybridoma cells were inoculated in each abdomen. About 10 days after the inoculation of cells, the abdomen of the mouse was obviously swollen. Before the mouse was on the verge of death, the ascites was collected and centrifuged to determine the antibody titer and purify the monoclonal antibody in the ascites; (7) Purification of monoclonal antibodies: Monoclonal antibodies were purified from mouse ascites using protein G agarose gel affinity purification.
5. Use of the monoclonal antibody 2G9 according to claim 1, 2 or 3 in preparing a product for detecting H10 subtype influenza virus.
6. The use according to claim 5, characterized in that: The product detects H10 subtype influenza virus in different samples through quantum dot fluorescent microsphere immunochromatography technology.
7. The use according to claim 6, characterized in that: The samples are poultry throat swabs, feces or allantoic fluid.
Citation Information
Patent Citations
Monoclonal antibody ZJU10-01 for resisting H10 sub-type avian influenza virus hemagglutinin protein and application thereof
CN112851803A
Monoclonal antibody 1F3 for resisting H10 subtype avian influenza virus hemagglutinin protein and application of monoclonal antibody 1F3 in detection
CN116063467A
Cited By
Anti-H10 subtype influenza virus hemagglutinin protein neutralizing monoclonal antibody 1E10 and application thereof
CN119613538A
Anti-h10 subtype influenza virus hemagglutinin protein neutralizing monoclonal antibody 1e10 and applications thereof
CN119613538B
